SMT201700021B - Metodi per il trattamento di malattie autoimmuni con antagonisti del dll4 - Google Patents

Metodi per il trattamento di malattie autoimmuni con antagonisti del dll4

Info

Publication number: SMT201700021B
Authority: SM; San Marino
Prior art keywords: dll4; antagonists; treatment; methods; autoimmune diseases
Prior art date: 2010-01-29

Application number

SM201700021T

Other languages

English (en)

Inventor

Dimitris Skokos

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-01-29

Filing date

2017-01-16

Publication date

2017-03-08

2017-01-16 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2017-03-08 Publication of SMT201700021B publication Critical patent/SMT201700021B/it

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Zoology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SM201700021T 2010-01-29 2017-01-16 Metodi per il trattamento di malattie autoimmuni con antagonisti del dll4 SMT201700021B (it)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US29980110P	2010-01-29	2010-01-29
US36168710P	2010-07-06	2010-07-06
US38869710P	2010-10-01	2010-10-01
PCT/US2011/022810 WO2011094465A1 (en)	2010-01-29	2011-01-28	Methods of treating autoimmune diseases with dll4 antagonists

Publications (1)

Publication Number	Publication Date
SMT201700021B true SMT201700021B (it)	2017-03-08

Family

ID=43925413

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SM201600412T SMT201600412B (it)	2010-01-29	2011-01-28	Metodi per il trattamento del diabete con antagonisti del dll4
SM20170021T SMT201700021T1 (it)	2010-01-29	2011-01-28	Metodi per il trattamento di malattie autoimmuni con antagonisti del dll4
SM201700021T SMT201700021B (it)	2010-01-29	2017-01-16	Metodi per il trattamento di malattie autoimmuni con antagonisti del dll4

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
SM201600412T SMT201600412B (it)	2010-01-29	2011-01-28	Metodi per il trattamento del diabete con antagonisti del dll4
SM20170021T SMT201700021T1 (it)	2010-01-29	2011-01-28	Metodi per il trattamento di malattie autoimmuni con antagonisti del dll4

Country Status (29)

Country	Link
US (3)	US8765125B2 (it)
EP (2)	EP2528945B1 (it)
JP (2)	JP5997613B2 (it)
KR (2)	KR101797918B1 (it)
CN (2)	CN102947336B (it)
AR (1)	AR080026A1 (it)
AU (2)	AU2011210771B2 (it)
BR (2)	BR112012018820A8 (it)
CA (2)	CA2787394C (it)
CY (2)	CY1118223T1 (it)
DK (2)	DK2528945T3 (it)
ES (2)	ES2609663T3 (it)
HR (2)	HRP20170249T1 (it)
HU (2)	HUE031432T2 (it)
IL (2)	IL220887A (it)
JO (2)	JO3183B1 (it)
LT (2)	LT2528945T (it)
MX (2)	MX343553B (it)
MY (2)	MY156538A (it)
PL (2)	PL2528945T3 (it)
PT (2)	PT2528945T (it)
RS (2)	RS55715B1 (it)
RU (2)	RU2587624C2 (it)
SG (4)	SG182528A1 (it)
SI (2)	SI2528946T1 (it)
SM (3)	SMT201600412B (it)
TW (2)	TWI600433B (it)
UY (1)	UY33206A (it)
WO (2)	WO2011094465A1 (it)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO347649B1 (no)	2006-12-14	2024-02-12	Regeneron Pharma	Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2011025964A2 (en)	2009-08-29	2011-03-03	Abbott Laboratories	Therapeutic dll4 binding proteins
US8883145B2 (en)	2009-10-16	2014-11-11	Oncomed Pharmaceuticals, Inc.	Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
JO3183B1 (ar) *	2010-01-29	2018-03-08	Regeneron Pharma	طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
UA112743C2 (uk)	2010-03-02	2016-10-25	Еббві Інк.	Терапевтичний dll4-зв'язувальний білок
LT3485903T (lt)	2011-09-23	2023-02-27	Mereo Biopharma 5, Inc.	Vegf/ dll4 surišantys agentai ir jų panaudojimas
KR101535341B1 (ko)	2012-07-02	2015-07-13	한화케미칼 주식회사	Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
MY194330A (en)	2012-11-01	2022-11-28	Abbvie Inc	Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
TW201438736A (zh) *	2012-11-14	2014-10-16	Regeneron Pharma	以ｄｌｌ４拮抗劑治療卵巢癌之方法
US10184010B2 (en)	2013-07-09	2019-01-22	Ablbio	Dual-targeting protein binding specifically to DLL4 and VEGF and use thereof
JP6560200B2 (ja) *	2013-10-17	2019-08-14	ザジェネラルホスピタルコーポレイション	自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物
WO2015154795A1 (en) *	2014-04-08	2015-10-15	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Combination therapy for the treatment of autoimmune diseases
EP3212233B1 (en)	2014-10-31	2020-06-24	Oncomed Pharmaceuticals, Inc.	Combination therapy for treatment of disease
AU2016326609B2 (en)	2015-09-23	2023-03-09	Mereo Biopharma 5, Inc.	Methods and compositions for treatment of cancer
US11446262B2 (en)	2018-11-29	2022-09-20	Debora Zucco Sassi Yonezawa Siviglia	Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination
EP3886856A4 (en) *	2018-11-29	2022-01-19	Zucco Sassi Yonezawa Siviglia, Debora	METHOD FOR TREATING OR PREVENTING SEIZURES ASSOCIATED WITH AN EPILEPTIC DISORDER
JPWO2022210802A1 (it) *	2021-03-30	2022-10-06
WO2023159166A1 (en) *	2022-02-18	2023-08-24	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Single-domain antibodies (nanobodies) targeting the notch ligand dll4 and methods of their use
WO2025212726A2 (en)	2024-04-04	2025-10-09	Compass Therapeutics, Inc.	Combination of antibodies targeting dll4/vegf and cd137 agonists or anti-pd1/anti-pd-l1 antibodies for the treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6927044B2 (en)	1998-09-25	2005-08-09	Regeneron Pharmaceuticals, Inc.	IL-1 receptor based cytokine traps
US7138370B2 (en)	2001-10-11	2006-11-21	Amgen Inc.	Specific binding agents of human angiopoietin-2
EP1505977B1 (en) *	2002-05-21	2014-09-10	Gilead Sciences, Inc.	Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes
US7850962B2 (en)	2004-04-20	2010-12-14	Genmab A/S	Human monoclonal antibodies against CD20
US20060134121A1 (en)	2004-10-29	2006-06-22	Gavin Thurston	DII4 antagonists, assays, and therapeutic methods thereof
DK1962895T3 (da)	2005-12-16	2013-03-04	Regeneron Pharma	TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
HRP20120175T1 (hr)	2006-06-02	2012-03-31	Regeneron Pharmaceuticals	Antitijela s visokim afinitetom za humani il-6 receptor
MX2008015541A (es) *	2006-06-06	2008-12-18	Genentech Inc	Anticuerpos anti-dll4 y metodos que los usan.
US20080014196A1 (en)	2006-06-06	2008-01-17	Genentech, Inc.	Compositions and methods for modulating vascular development
JP5529536B2 (ja) *	2006-08-07	2014-06-25	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	虚血性障害又は血管不全の治療におけるＤｌｌ４アンタゴニストの使用
US7750124B2 (en)	2006-09-29	2010-07-06	Oncomed Pharmaceuticals, Inc.	Anti-human DLL4 antibodies and compositions
NO347649B1 (no) *	2006-12-14	2024-02-12	Regeneron Pharma	Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2011025964A2 (en)	2009-08-29	2011-03-03	Abbott Laboratories	Therapeutic dll4 binding proteins
JO3183B1 (ar) *	2010-01-29	2018-03-08	Regeneron Pharma	طرق لمعالجة أمراض المناعة الذاتية مضادات dll4

2011
- 2011-01-23 JO JOP/2011/0021A patent/JO3183B1/ar active
- 2011-01-26 AR ARP110100250A patent/AR080026A1/es unknown
- 2011-01-28 MX MX2012008740A patent/MX343553B/es active IP Right Grant
- 2011-01-28 HU HUE11701933A patent/HUE031432T2/en unknown
- 2011-01-28 JP JP2012551293A patent/JP5997613B2/ja active Active
- 2011-01-28 AU AU2011210771A patent/AU2011210771B2/en active Active
- 2011-01-28 SM SM201600412T patent/SMT201600412B/it unknown
- 2011-01-28 CA CA2787394A patent/CA2787394C/en active Active
- 2011-01-28 RS RS20170142A patent/RS55715B1/sr unknown
- 2011-01-28 RS RS20170036A patent/RS55595B1/sr unknown
- 2011-01-28 TW TW105101963A patent/TWI600433B/zh not_active IP Right Cessation
- 2011-01-28 BR BR112012018820A patent/BR112012018820A8/pt not_active Application Discontinuation
- 2011-01-28 EP EP11701735.0A patent/EP2528945B1/en active Active
- 2011-01-28 HR HRP20170249TT patent/HRP20170249T1/hr unknown
- 2011-01-28 ES ES11701933.1T patent/ES2609663T3/es active Active
- 2011-01-28 LT LTEP11701735.0T patent/LT2528945T/lt unknown
- 2011-01-28 PT PT117017350T patent/PT2528945T/pt unknown
- 2011-01-28 PL PL11701735T patent/PL2528945T3/pl unknown
- 2011-01-28 TW TW100103219A patent/TWI564019B/zh not_active IP Right Cessation
- 2011-01-28 MY MYPI2012003169A patent/MY156538A/en unknown
- 2011-01-28 US US13/015,637 patent/US8765125B2/en active Active
- 2011-01-28 SG SG2012052056A patent/SG182528A1/en unknown
- 2011-01-28 KR KR1020127022496A patent/KR101797918B1/ko not_active Expired - Fee Related
- 2011-01-28 ES ES11701735.0T patent/ES2605430T3/es active Active
- 2011-01-28 KR KR1020127022506A patent/KR101832118B1/ko not_active Expired - Fee Related
- 2011-01-28 US US13/015,652 patent/US8889133B2/en active Active
- 2011-01-28 UY UY0001033206A patent/UY33206A/es not_active Application Discontinuation
- 2011-01-28 RU RU2012136817/10A patent/RU2587624C2/ru not_active IP Right Cessation
- 2011-01-28 WO PCT/US2011/022810 patent/WO2011094465A1/en not_active Ceased
- 2011-01-28 SI SI201131020A patent/SI2528946T1/sl unknown
- 2011-01-28 BR BR112012018766A patent/BR112012018766A2/pt active Search and Examination
- 2011-01-28 SI SI201131011A patent/SI2528945T1/sl unknown
- 2011-01-28 SM SM20170021T patent/SMT201700021T1/it unknown
- 2011-01-28 SG SG10201500416RA patent/SG10201500416RA/en unknown
- 2011-01-28 HR HRP20170130TT patent/HRP20170130T1/hr unknown
- 2011-01-28 CN CN201180016820.4A patent/CN102947336B/zh not_active Expired - Fee Related
- 2011-01-28 RU RU2012136816/10A patent/RU2587620C2/ru not_active IP Right Cessation
- 2011-01-28 WO PCT/US2011/022817 patent/WO2011094467A2/en not_active Ceased
- 2011-01-28 SG SG10201500404QA patent/SG10201500404QA/en unknown
- 2011-01-28 HU HUE11701735A patent/HUE032985T2/en unknown
- 2011-01-28 PL PL11701933T patent/PL2528946T3/pl unknown
- 2011-01-28 SG SG2012052049A patent/SG182527A1/en unknown
- 2011-01-28 CN CN2011800165511A patent/CN102884081A/zh active Pending
- 2011-01-28 DK DK11701735.0T patent/DK2528945T3/en active
- 2011-01-28 LT LTEP11701933.1T patent/LT2528946T/lt unknown
- 2011-01-28 MY MYPI2012003168A patent/MY156353A/en unknown
- 2011-01-28 EP EP11701933.1A patent/EP2528946B1/en active Active
- 2011-01-28 JP JP2012551294A patent/JP5883801B2/ja active Active
- 2011-01-28 PT PT117019331T patent/PT2528946T/pt unknown
- 2011-01-28 MX MX2012008638A patent/MX343555B/es active IP Right Grant
- 2011-01-28 CA CA2787615A patent/CA2787615C/en active Active
- 2011-01-28 DK DK11701933.1T patent/DK2528946T3/en active
- 2011-01-28 AU AU2011210773A patent/AU2011210773B2/en active Active
2012
- 2012-07-11 IL IL220887A patent/IL220887A/en not_active IP Right Cessation
- 2012-07-11 IL IL220889A patent/IL220889A/en not_active IP Right Cessation
2014
- 2014-05-22 US US14/285,409 patent/US20140255429A1/en not_active Abandoned
2016
- 2016-11-14 CY CY20161101167T patent/CY1118223T1/el unknown
2017
- 2017-01-04 CY CY20171100010T patent/CY1118551T1/el unknown
- 2017-01-16 SM SM201700021T patent/SMT201700021B/it unknown
- 2017-03-19 JO JOP/2017/0065A patent/JO3242B1/ar active

Also Published As

Publication number	Publication date
SI2528946T1 (sl)	2017-01-31
EP2528946A1 (en)	2012-12-05
AR080026A1 (es)	2012-03-07
TW201136601A (en)	2011-11-01
TWI564019B (zh)	2017-01-01
CN102884081A (zh)	2013-01-16
MY156353A (en)	2016-02-15
ES2605430T3 (es)	2017-03-14
PT2528945T (pt)	2016-12-14
JO3183B1 (ar)	2018-03-08
HRP20170249T1 (hr)	2017-04-07
SMT201600412B (it)	2017-01-10
WO2011094465A1 (en)	2011-08-04
JO3242B1 (ar)	2018-03-08
US20110189176A1 (en)	2011-08-04
WO2011094467A2 (en)	2011-08-04
IL220887A (en)	2017-07-31
JP5883801B2 (ja)	2016-03-15
JP2013518122A (ja)	2013-05-20
KR20120123745A (ko)	2012-11-09
CA2787394A1 (en)	2011-08-04
WO2011094467A3 (en)	2011-12-22
AU2011210773A1 (en)	2012-08-23
IL220889A (en)	2017-07-31
SI2528945T1 (sl)	2017-01-31
EP2528946B1 (en)	2016-11-16
US20140255429A1 (en)	2014-09-11
SG182527A1 (en)	2012-08-30
MX343555B (es)	2016-11-10
CN102947336A (zh)	2013-02-27
LT2528945T (lt)	2017-01-25
HUE032985T2 (en)	2017-11-28
WO2011094465A4 (en)	2011-09-22
JP2013518123A (ja)	2013-05-20
UY33206A (es)	2011-08-31
CA2787615C (en)	2019-01-15
EP2528945A2 (en)	2012-12-05
HUE031432T2 (en)	2017-07-28
CN102947336B (zh)	2015-12-02
TWI600433B (zh)	2017-10-01
CY1118223T1 (el)	2017-06-28
BR112012018766A2 (pt)	2017-01-10
RS55595B1 (sr)	2017-06-30
LT2528946T (lt)	2017-01-25
US20110189200A1 (en)	2011-08-04
IL220889A0 (en)	2012-09-24
MX343553B (es)	2016-11-10
CA2787394C (en)	2019-01-08
PL2528945T3 (pl)	2017-02-28
AU2011210773B2 (en)	2015-11-19
RU2012136817A (ru)	2014-03-10
HRP20170130T1 (hr)	2017-03-24
RU2587620C2 (ru)	2016-06-20
SMT201700021T1 (it)	2017-03-08
PT2528946T (pt)	2016-12-14
US8765125B2 (en)	2014-07-01
MX2012008740A (es)	2012-08-31
KR101797918B1 (ko)	2017-11-15
DK2528945T3 (en)	2017-02-06
RU2587624C2 (ru)	2016-06-20
ES2609663T3 (es)	2017-04-21
CY1118551T1 (el)	2017-07-12
DK2528946T3 (en)	2017-02-20
SG10201500416RA (en)	2015-04-29
MX2012008638A (es)	2012-12-05
CA2787615A1 (en)	2011-08-04
BR112012018820A2 (pt)	2017-01-10
RU2012136816A (ru)	2014-03-10
TW201615207A (zh)	2016-05-01
SG10201500404QA (en)	2015-03-30
JP5997613B2 (ja)	2016-09-28
RS55715B1 (sr)	2017-07-31
SG182528A1 (en)	2012-08-30
BR112012018820A8 (pt)	2018-03-13
AU2011210771B2 (en)	2015-12-10
EP2528945B1 (en)	2016-10-26
PL2528946T3 (pl)	2017-04-28
US8889133B2 (en)	2014-11-18
AU2011210771A1 (en)	2012-08-23
KR20130008017A (ko)	2013-01-21
MY156538A (en)	2016-02-26
KR101832118B1 (ko)	2018-02-26

Publication	Publication Date	Title
SMT201700021B (it)	2017-03-08	Metodi per il trattamento di malattie autoimmuni con antagonisti del dll4
LTC2785706I2 (lt)	2023-07-10	Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
EP2856376A4 (en)	2016-01-27	DETERMINING THE CLINICAL SIGNIFICANCE OF SEQUENCE VARIANTS
DK2919796T3 (da)	2021-05-31	Brug af akkermansia til behandling af stofskiftesygdomme
CO6791605A2 (es)	2013-11-14	Métodos de tratamiento de trastornos asociados con el fgf21
SMT201600078B (it)	2016-04-29	Antagonista del recettore per cgrp
IT1402748B1 (it)	2013-09-18	Procedimento per la raffinazione del greggio
IL229858B (en)	2019-01-31	Polypeptides and uses thereof for tratment of autoimmune disorders and infection
SMT201500057B (it)	2015-05-05	Uso della biotina per il trattamento della sclerosi multipla
PL2768859T3 (pl)	2018-07-31	Antagoniści IL17C do leczenia zaburzeń zapalnych
SMT201500296B (it)	2016-01-08	Antagonisti del recettore trpm8
ITMI20120445A1 (it)	2012-09-25	Dispositivo e procedimento per la produzione di spazzole circolari
SMT201600235B (it)	2016-08-31	Predittori per il trattamento del cancro
PL2790712T3 (pl)	2017-04-28	Podpopulacja ludzkich monocytów do leczenia uszkodzenia ośrodkowego układu nerwowego
PL2904009T3 (pl)	2019-06-28	Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w
ITRM20120530A1 (it)	2014-05-01	Compounds for use in the treatment of parasitic diseases
ITRM20120473A1 (it)	2014-04-05	Use of glycerophosphoinositols for the treatment of septic shock
SMT201700072B (it)	2017-03-08	Utilizzo del pidotimod per il trattamento della psoriasi
IT1398032B1 (it)	2013-02-07	Transferrina per il trattamento di malattie autoimmuni.
PL2956136T3 (pl)	2019-06-28	D-fagomina do zapobiegania wystąpienia chorób autoimmunologicznych
PL2555790T3 (pl)	2016-12-30	ZASTOSOWANIE LECZNICZE ß2-MIKROGLOBULINY
IL241934A (en)	2017-11-30	Inhibitory peptides for the treatment of inflammatory diseases
SMT201400174B (it)	2015-01-15	Esteri del metronidazolo per il trattamento della rosacea
IL222690A0 (en)	2012-12-31	Treatment of autoimmune diseases
IT1406405B1 (it)	2014-02-21	Molecole peptidiche per il trattamento di patologie mitocondriali